Marker Therapeutics (MRKR) Accumulated Expenses (2013 - 2023)
Marker Therapeutics (MRKR) posted quarterly Accumulated Expenses of $610000.0 for Q2 2023, down 61.02% year-over-year from $1.6 million in Q2 2022, and up 34.36% quarter-over-quarter from $454000.0 in Q1 2023.
Marker Therapeutics (MRKR) Accumulated Expenses (2013 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Accumulated Expenses for 8 consecutive years, with $610000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Accumulated Expenses fell 61.02% year-over-year to $610000.0; the TTM figure through Jun 2023 stood at $610000.0 (down 61.02% YoY), while the FY2022 annual figure was $750000.0, down 63.5% from the prior year.
- Accumulated Expenses climbed to $610000.0 in Q2 2023 per MRKR's latest filing, from $454000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $2.4 million in Q3 2021 and bottomed at $323000.0 in Q4 2019.
- Historically, Accumulated Expenses has averaged $1.1 million across 5 years, with a median of $858000.0 in 2020.
- Annual changes were most pronounced in 2020 — Accumulated Expenses jumped 424.46% — and 2022, when it tumbled 63.5%.
- Marker Therapeutics' Accumulated Expenses stood at $323000.0 in 2019, then surged by 424.46% to $1.7 million in 2020, then grew by 21.31% to $2.1 million in 2021, then sank by 63.5% to $750000.0 in 2022, then declined by 18.67% to $610000.0 in 2023.
- Business Quant data shows MRKR's Accumulated Expenses at $610000.0 in Q2 2023, $454000.0 in Q1 2023, and $750000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 610,000.00 |
| Mar 31, 2023 | 454,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Sep 30, 2022 | 2.31 Mn |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 747,000.00 |
| Dec 31, 2021 | 2.06 Mn |
| Sep 30, 2021 | 2.40 Mn |
| Jun 30, 2021 | 1.11 Mn |
| Mar 31, 2021 | 827,000.00 |
| Dec 31, 2020 | 1.69 Mn |
| Sep 30, 2020 | 1.39 Mn |
| Jun 30, 2020 | 858,000.00 |
| Mar 31, 2020 | 616,000.00 |
| Dec 31, 2019 | 323,000.00 |
| Sep 30, 2019 | 1.06 Mn |
| Jun 30, 2019 | 781,000.00 |
| Dec 31, 2018 | 416,000.00 |
| Dec 31, 2015 | 492,000.00 |
| Dec 31, 2013 | 558,032.00 |